A noninvasive method for tissue stiffness quantification in small animals with shear wave elastography

一种利用剪切波弹性成像对小动物组织硬度进行无创定量的方法

基本信息

批准号：
9516302
负责人：
Tomasz Joseph Czernuszewicz
金额：
$ 3万
依托单位：
SONOVOL, INC.
依托单位国家：
美国
项目类别：
财政年份：
2017
资助国家：
美国
起止时间：
2017-09-05 至 2018-03-19
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9516302
关键词：
3D ultrasound Abdomen Acoustics Address Adopted Adoption Affect Americas Anatomy Animal Experimentation Animal Model Animals Autopsy Biological Biological Models Biological Sciences Breast Calibration Cardiac Clinic Clinical Clinical Trials Communities Community Developments Data Data Collection Devices Diagnosis Disease Disease model Elasticity Ensure Environment FDA approved Fibrosis Frequencies Funding Future Geometry Gold Hand Heating Histologic Human Image Imaging Device Imaging Phantoms Imaging Techniques Imaging technology In Vitro Knowledge Laboratories Laboratory Research Liver Liver Cirrhosis Liver Fibrosis Liver diseases Longitudinal Studies Malignant Neoplasms Manuals Measurement Measures Mechanics Methods Modeling Monitor Mus Organ Outcome Output Pathology Patients Penetration Pharmaceutical Preparations Phase Physiologic pulse Positioning Attribute Prostate Protocols documentation Publishing Radiology Specialty Reproducibility Research Research Personnel Resolution Robotics Rodent Rodent Model Scanning Sensitivity and Specificity Skin Software Tools Speed Staining method Stains Surface System Techniques Technology Temperature Testing Thyroid Gland Time Tissues Training Transducers Travel Ultrasonics Ultrasonography Variant Work animal imaging base cancer imaging choline deficient diet cohort cost design drug development elastography imaging platform imaging system improved in vivo innovation interest killings liver biopsy liver development mouse model novel pre-clinical prevent research and development response robot control skills success tool

项目摘要

Abstract Liver fibrosis, a hallmark of many liver diseases, affects millions of people in America every year, and annually kills tens of thousands of these patients. Despite very active research efforts, there still have been no specific antifibrotic drugs approved by the FDA. The liver disease and drug development communities do not currently have well-validated, low-cost, easy to use, noninvasive tools for studying liver fibrosis in preclinical rodent models making it challenging to execute high-quality longitudinal studies. To address this need, SonoVol Inc. proposes to develop a novel benchtop imaging system capable of providing rapid, noninvasive measurements of liver fibrosis in rodents with robotically-controlled shear wave elasticity imaging (SWEI). In SWEI, ultrasound pulses are used to generate shear waves in an organ an interest, and tissue stiffness can be inferred by monitoring the speed of the travelling waves. SWEI technology has been very successful in clinical trials and is starting to be adopted by abdominal radiology clinics around the world as a replacement for liver biopsy. While some preclinical SWEI products exist on the market today, all of them follow the conventional ultrasound paradigm of data collection – a trained sonographer uses a handheld probe and manually selects regions of interest to interrogate with SWEI. Making consistent and accurate measurements requires in depth knowledge of probe placement and sonographic technique, which academic biologists or drug researchers are unlikely to possess. Therefore, SonoVol will develop a device capable of fully-automated, non-contact SWEI that eliminates the need for a trained sonographer and will enable large scale adoption of this powerful technology in the preclinical liver diseases research community. To validate the new system, two different animal models for hepatic fibrosis will be evaluated, and the results compared to conventional postmortem assessments of liver fibrosis. This technology represents an innovative combination of a widefield 3D robotic ultrasound imaging system and noninvasive shear wave elastography. Furthermore, the technology can be applied in the future to many other diseases, including cancer or cardiac models, increasing the potential market and impact on the field.

抽象的肝纤维化是许多肝脏疾病的标志，每年影响数以百万计的美国人尽管研究工作非常积极，但每年都会导致数以万计的患者死亡。目前尚无特定的抗纤维化药物获得 FDA 批准。药物开发界目前没有经过充分验证的、低成本的、易于使用的、在临床前啮齿动物模型中研究肝纤维化的非侵入性工具使其具有挑战性进行高质量的纵向研究。为了满足这一需求，SonoVol Inc. 提议开发一种新型台式成像系统能够快速、无创地测量啮齿动物的肝纤维化机器人控制的剪切波弹性成像 (SWEI) 在 SWEI 中，超声脉冲是。用于在感兴趣的器官中产生剪切波，并且组织硬度可以通过以下方式推断 SWEI技术在以下方面非常成功临床试验，并开始被世界各地的腹部放射诊所采用虽然目前市场上存在一些临床前 SWEI 产品，所有这些都遵循传统的超声数据收集范式——训练有素的超声医师使用手持式探头并手动选择要询问的感兴趣区域 SWEI。进行一致且准确的测量需要对探头有深入的了解。学术生物学家或药物研究人员正在使用的放置和超声技术不太可能拥有。因此，SonoVol 将开发一种能够全自动、非接触式 SWEI 的设备，消除了对训练有素的超声波技师的需求，并将使这种技术得以大规模采用临床前肝病研究界的强大技术来验证新的技术。系统将评估两种不同的肝纤维化动物模型，并得出结果与传统的肝纤维化死后评估相比，该技术代表了这一点。宽视场 3D 机器人超声成像系统和无创性的创新组合此外，该技术未来可应用于许多领域。其他疾病，包括癌症或心脏病模型，增加潜在市场和影响在球场上。